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Analysis of high-depth sequence data for
studying viral diversity: a comparison of next
generation sequencing platforms using
Segminator II
John Archer1*, Greg Baillie2, Simon J Watson2, Paul Kellam2,3, Andrew Rambaut4,5 and David L Robertson1*
Abstract
Background: Next generation sequencing provides detailed insight into the variation present within viral
populations, introducing the possibility of treatment strategies that are both reactive and predictive. Current
software tools, however, need to be scaled up to accommodate for high-depth viral data sets, which are often
temporally or spatially linked. In addition, due to the development of novel sequencing platforms and chemistries,
each with implicit strengths and weaknesses, it will be helpful for researchers to be able to routinely compare and
combine data sets from different platforms/chemistries. In particular, error associated with a specific sequencing
process must be quantified so that true biological variation may be identified.
Results: Segminator II was developed to allow for the efficient comparison of data sets derived from different
sources. We demonstrate its usage by comparing large data sets from 12 influenza H1N1 samples sequenced on
both the 454 Life Sciences and Illumina platforms, permitting quantification of platform error. For mismatches
median error rates at 0.10 and 0.12%, respectively, suggested that both platforms performed similarly. For insertions
and deletions median error rates within the 454 data (at 0.3 and 0.2%, respectively) were significantly higher than
those within the Illumina data (0.004 and 0.006%, respectively). In agreement with previous observations these
higher rates were strongly associated with homopolymeric stretches on the 454 platform. Outside of such regions
both platforms had similar indel error profiles. Additionally, we apply our software to the identification of low
frequency variants.
Conclusion: We have demonstrated, using Segminator II, that it is possible to distinguish platform specific error
from biological variation using data derived from two different platforms. We have used this approach to quantify
the amount of error present within the 454 and Illumina platforms in relation to genomic location as well as
location on the read. Given that next generation data is increasingly important in the analysis of drug-resistance
and vaccine trials, this software will be useful to the pathogen research community. A zip file containing the
source code and jar file is freely available for download from http://www.bioinf.manchester.ac.uk/segminator/.
Background
Sequencing platforms such as the 454 Life Sciences GS-
FLX [1] and Illumina [2] are providing a previously
unprecedented insight into the extent of pathogen varia-
tion [3-7]. This is due to the depth of coverage that can
be obtained across individual genes or genomes [8], as
well as the ability to analyze large numbers of samples
simultaneously [9,10]. Within chronic viral infections,
such as HIV-1 and HCV, the study of variation is
important as it has been directly associated with both
disease progression and the outcome of treatment
[11-14]. These sequencing platforms have the potential
to accurately quantify the variation within viral popula-
tions [15,16], including those sampled through time
[3,17], and from differing compartments within the host
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[18], thus, providing a more complete picture of viral
evolution. This has applications for the development of
treatment strategies that are both reactive and predic-
tive. Reactive in that the information derived from indi-
vidual hosts can be incorporated into the optimization
of current drug treatment regimes [14,19-21]. Predictive
in that the likelihood of the emergence of resistant var-
iants can be calculated and incorporated into strategies
such as the algorithmic design of therapeutic vaccines
[22,23].
However, prior to the practical and routine application
of current sequencing technologies to the characterization
of patterns of variation, a number of non-trivial challenges
need to be overcome [24]. Primarily this involves the
detection of error introduced during sequencing [25,26],
and the separation of this from real genetic variation. This
issue is particularly acute for RNA viruses within an indivi-
dual host for which the degree of genetic variation may be
on the same order as the error rate. The extent and nature
of sequencing error varies between platforms [27]. For
example, the 454 technology utilizes a sequencing by-
synthesis method during which the incorporation of cycli-
cally delivered nucleotides into the growing DNA strand,
via pyrophosphate liberation, is measured [28]. In regions
where the complement strand contains a homopolymeric
stretch, the strength of the signal is proportional to the
number of bases incorporated. Ambiguities in signal inten-
sity are most frequently manifested as under- and over-
calls on the length of these stretches [29]. An overall error
rate of about 1% has been observed [7,25] which has been
partitioned into insertion (0.7%), deletion (0.2%) and mis-
match error (0.1%). Unlike the 454 platform, sequences
generated on the Illumina platform are extended one base
at a time [28], thus, under- and over-calls are uncommon.
Mismatch error, however, has been observed [26,27], and,
because of the high coverage that is achievable, the quanti-
fication of the rate at which this error occurs is particularly
relevant when attempting to identify low frequency genetic
variants.
The development of an accurate, dynamic picture of
viral evolution within the host has also been hampered
by the logistics of data management. The many map-
ping, assembly and analysis programs available [30,31]
primarily have the goal of obtaining an accurate esti-
mate of a genomic sequence or detecting variation at
the allelic level. Other commercially available packages
such as Geneius [32] and CLC Genomics Workbench
http://www.clcbio.com/, that do offer tools to analyze
sequence variability, have limited capacity to account for
temporally sampled viral data. At the time of writing no
freely available, generally applicable software exists that
addresses the task of detecting and characterizing the
high levels of genetic variation encountered within
rapidly evolving viral populations using data that has
either been temporally or compartmentally sampled.
Prior to our current work we presented a framework,
for the mapping of the short sequence segments (reads)
generated on the 454 platform, which was applied to the
detection of clusters of low frequency drug resistant
forms [3]. Here we extend this framework so that it (i)
is applicable to viral data generated on the Illumina
platform (and other sequencing platforms), (ii) outputs a
range of metrics for characterizing variability including
base, indel and codon frequencies, coverage and quality
scores and (iii) allows for multiple data sets to be mana-
ged within a project permitting comparative analysis. To
demonstrate the usefulness of our software we assess
platform-induced variation present within reads derived
from 12 Influenza A H1N1/09 infected individuals. For
each individual, because the same sample was used for
read amplification on both the 454 and Illumina plat-
forms, any variation associated solely with a single plat-
form can be considered as potential sequencing error.
H1N1 genomes are particularly useful for characterizing
insertion and deletion error that has been introduced by
the sequencing platform because indels are rare in this
data [5].
Implementation
Implemented in Java the software, Segminator II, along
with the source code, is available from http://www.
bioinf.manchester.ac.uk/segminator/. A graphical user
interface (Figure 1) resides on top of an underlying data
Figure 1 Segminator II user interface. The table in the center of
the GUI displays information that is available after read mapping
and alignment. Above the table are the dropdown boxes that allow
navigation between projects and data sets. Below the table
heatmaps showing cover, entropy, and insertion, deletions and non-
consensus frequencies are located. On the right hand side the
“Treedar” feature which dynamically generates a neighbor joining
tree as the user scrolls along the genome is located. Below this are
data set summary panel and the table scan panel, the latter which
can be used to query sites based on variation, quality and
homopolymeric stretch size (grey rows). On the top right buttons to
change the display mode to the read view or tree view are
observed.
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management framework providing convenient access to
the main features of the software. Components of the
framework can be incorporated within automated bioin-
formatics pipelines through direct use of the core pack-
age (available with the source code). Within the
framework individual reads are stored post-mapping as
lists of polymorphisms in relation to a user-defined
reference sequence (Figure 2). As a consequence the
majority of characters that are identical to the template,
representing redundant information, do not need to be
stored. Selection of a reference sequence that is proxi-
mal to the data set is, therefore, important not only for
improved mapping [3], but also for the reduction in the
quantity of information that needs to be stored. The sto-
rage of polymorphic characters in this manner allows for
the efficient extraction of data from the assembly. For
example, reads themselves spanning a particular location
of the template can be quickly reconstructed either (i)
with all insertions in relation to the template removed,
thus, maintaining site compatibility between reads or (ii)
in its original format, where the read start location is
maintained but inter-read compatibility between indivi-
dual sites is not guaranteed. An immediate application
of the former is the ‘Treedar’ feature of the user inter-
face (Figure 1) which uses pairwise distances between
reads that have been aligned to the template in order to
generate a rough, but dynamically generated, phyloge-
netic tree as the user scrolls along the virus genome.
This tree can be used to rapidly identify regions of the
genome with divergent portions of sequence space prior
to the localized application of full phylogenetic recon-
struction techniques. Additionally access to information
pertaining to the classification of variation at individual
sites (or codons), along with associated quality scores, is
made possible without the need to reconstruct complete
alignments.
Prior to read storage and variant detection individual
reads in fastq format, are required to be mapped to the
template sequence. This is performed using a combina-
tion of k-mer matching and pairwise alignment (Figure
3). Through the user interface multiple data sets may be
linked to the same template sequence. Setting up a pro-
ject with its associated template sequence does this as
subsequent data sets added to the project are then
mapped to the associated template. If the user is con-
cerned about failing to map reads because of divergence
from the template, which is especially relevant to rapidly
evolving viral genomes such as HIV-1 [3], there is a
parameter (under the Parameters- > Miscellaneous
menu option) that when set to true, will take a consen-
sus at each site of the template after the first mapping
and then remap reads to this consensus sequence. A full
description of the features of the user interface, as well
as the parameters used, is available on the website. To
demonstrate the usage of our framework we have
applied it in a case study to 12 H1N1 data sets derived
from samples sequenced on both the 454 and Illumina
platforms.
Case study: data sets
Nasal swabs were taken from individuals within the UK
presenting with pandemic H1N1/2009. Virus genome
RNA was extracted from these swabs using standard
methods. Influenza genomes were RT-PCR amplified
using the method based on [33]. Reactions were per-
formed in a volume of 50 μl under an overlay of 20 μl
Vapor-Lock (Qiagen), and contained 5.0 μl of RNA iso-
lated from clinical material, and final concentrations of
1× SuperScript® III One-Step RT-PCR reaction buffer,
0.5 μM each primer and 1.0 μl SuperScript® III RT/Pla-
tinum® Taq High Fidelity Enzyme Mix. Thermal cycling
conditions were: reverse transcription at 42°C for 15
minutes, 55°C for 15 minutes, 60°C for 5 minutes; initial
denaturation/enzyme activation of 94°C for 2 minutes;
five cycles of 94°C for 30 seconds, 45°C for 30 seconds,
slow ramp (0.5°C/sec) to 68°C, 68°C for 3 minutes; 30
cycles 94°C for 30 seconds, 57°C for 30 seconds, 68°C
for 3 minutes; and final extension of 68°C for 5 min.
RT-PCR products were used to generated multiplex
identifier (MID) tagged libraries for 454 (454 Life
Sciences, Branford, CT) or Illumina (Illumina Inc., San
Diego, CA) sequencing, according to the manufacturers’
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instructions. 454 sequencing was performed on the Gen-
ome Sequencer FLX system. Illumina sequencing was
performed on the Genome Analyzer I system with 54
bp paired-end reads. In total there were 24 data sets, 12
from each platform. The number of reads available for
each data set prior to mapping ranged from 832,117 to
2,827,392 for the Illumina platform, and from 4,569 to
14,758 for the 454 platform (Table 1). These are avail-
able in fastq format from our website.
Case study: template creation, mapping and alignment
To construct a reference sequence, for each genomic
segment of the H1N1 genome, a sample of data-all
available full length US sequences-were downloaded
from GenBank http://www.ncbi.nlm.nih.gov/genbank/,
aligned using Muscle [34] and a consensus sequence
generated. The number of sequences included for each
gene was: PB2: 1401, PB1: 1397, PA: 1387, HA: 1578,
NP: 1461, NA: 1586, MP: 1490 and NS: 1409. Consen-
sus sequences from each were concatenated together to
produce a genome length template of length 13,284
nucleotides. At each concatenation point, a string of Ns
was incorporated in order to separate the segments for
visualization purposes; these were ignored in the read
mapping. For each of the 12 samples, reads from both
platforms were separately mapped to the template using
our framework (Figure 2), following which a data set
specific consensus sequence was generated by maintain-
ing the most frequent residue present at each site. Reads
were then remapped and aligned to the consensus
sequence, which resulted in the final assemblies used in
downstream analysis. The parameters for the k-mer
matching step were k-mer length, k-mer density (mini-
mum number of k-mer hits before a location is consid-
ered) and k-mer skip (rather than search every k-mer
within the read every ith k-mer is used, where i is the
skip parameter); the values set for these were 8, 2 and 2,
respectively. Note, for conserved data the speed of the
mapping can be increased using the skip parameter as
searching every k-mer to find the approximate location
of a read leads to redundancy. For the pairwise align-
ment step the parameters were: match, gap open and
gap extension scores as well as the value for transver-
sions and transitions with the values: 1, -2, -0.5, 2 and 1,
respectively.
Case study: results
The number of successfully mapped reads from each
sample is presented in Table 1. For each data set, fol-
lowing pooling of the data by platform, genomic cover-
age was calculated (Figure 4A). The median length of
the reads within the combined 454 data sets was 182
nucleotides (Figure 4B), which varied only slightly within
individual data sets (Figure 4B, inset). Reads from the
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locations
template 
k-mers
1, 10, 30
50, 100, 122
8, 90, 96, 200
60, 70, 140
22, 35, 95
112, 128
148, 166
55, 85, 117
x, y, z
a, b, c
x, y, z
a, b, c
read
read 
k-mers
fr
eq
ue
nc
y
approx.
start
approx.
end
data set containing reads
variant detection
for each k-mer in the read
look up locations within
template library
all reads processed == true no
read
clip template
pairwise align
generate profile
add to assembly
template
consensus generated == trueconsensus
generation
replace template
with
consensus 
yes
yes
no
unmapped read
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Illumina platform were all of length 54 nucleotides. To
characterize the general diversity present within our 12
samples the per-site entropy was calculated across data
pooled according to platform using the standard
Shannon entropy measure. For comparison, per-site
entropy was also calculated within the sample of Gen-
Bank data used during the generation of the reference
sequences. For both platforms the entropy present (454
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0
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Figure 4 Initial mapping and data characterization. (A) Normalized read coverage across the eight genomic segments of the H1N1 genome
(data from each sample has been combined). Coverage obtained from the 454 platform is displayed above the x-axis while the coverage
obtained on the Illumina platform is mirrored below. In each case the maximum value is depicted in brackets. Genomic segments are shown
along the bottom of the plot. (B) Read length variation across the 454 data following sample pooling. The inset box and whisker plot shows the
read lengths within each individual sample labeled a to l and corresponding to samples 511 to 580, respectively (Table 1). (C) Entropy present
within data obtained from the 454 and Illumina platforms as well as that present within in a sample of H1N1 data from GenBank.
Table 1 Sample ID’s and read numbers before and after mapping
Illumina 454 Life Sciences
Sample ID No. of reads No. of reads mapped (%) No. of reads No. of reads mapped (%)
511 1160281 875620 (75) 4569 4082 (89)
512 2266246 1586144 (70) 5173 4286 (83)
513 2606959 1794027 (69) 9679 8972 (93)
533 1751178 1264611 (72) 6974 6339 (91)
534 1428288 1015404 (71) 7642 7093 (93)
535 832117 655689 (79) 10176 9444 (93)
538 1387955 1115917 (80) 6690 6282 (94)
540 2827392 2136159 (76) 5419 4985 (92)
541 1574181 1276311 (81) 5151 4835 (94)
578 2870922 2130089 (74) 17586 16307 (93)
579 1664978 1208913 (73) 14758 13657 (93)
580 1854234 1378426 (74) 14124 12990 (92)
Unmapped and mapped reads
Archer et al. BMC Bioinformatics 2012, 13:47
http://www.biomedcentral.com/1471-2105/13/47
Page 5 of 11
median: 0.0192; Illumina median: 0.0172) was observed
to be higher than that within the database data (median:
0.0085) (Figure 4C), thus, highlighting the need to char-
acterize platform dependent variation within the read
data. Note, the same pattern of mutations was seen
when samples were analysed individually.
The ratio between the frequency of minority variants
and the population consensus at each genomic site was
calculated using data sets pooled according to platform.
Here pooling was performed, as we were interested in
characterizing differences occurring between platforms,
not the explicit detection of variants within each sample.
In order to identify platform-induced variation these
ratios, after normalization for differences in coverage,
were subtracted at each genomic site (Figure 5). Because
the same samples had been used for sequencing on both
platforms, differences that deviate from zero are indica-
tive of platform specific variation, with positive values
indicating variation unique to the 454 platform and vice
versa. When ratios obtained from each platform are
compared, the extent of platform dependent variation is
highlighted (Figure 6A). The median for insertions and
deletions within the data generated on the 454 platform,
at 0.0025 and 0.0019, respectively, were significantly
higher (p < 0.001, Wilcox rank sum test) than those
from insertions and deletions within the data generated
on the Illumina platform (0.00004 and 0.00006, respec-
tively). For mismatches, the median rate obtained on the
454 platform, at 0.0010, was very similar to that
observed with the Illumina data (0.0012). When sites are
divided into two categories: (i) those that are part of a
homopolymeric stretch of length three or more (hps+)
and (ii) those that are outside of these regions (hps-),
the 454 platform shows significantly higher variation
occurring within the hps+ category (Figure 6B). For
insertions, deletions and mismatches the median within
the hps+ sites were 0.0179, 0.0145 and 0.0016, respec-
tively, while outside of these regions the medians were
0.0025, 0.0019 and 0.001, respectively. Despite the far
higher coverage, data from the Illumina platform con-
tained very few insertions and deletions, and no differ-
ence between hps+ and hps- was observed.
On mapping change from a consensus to a minority
variant at sites on the template to locations on the
underlying reads it was observed that within the 454
data, with the exception of the very start of the reads,
there is a relatively uniform distribution across the read
length, following a random expectation (Figure 7A, C
and 7D). For deletions the single peak, at location 62,
(Figure 7C) was attributed to a homopolymeric run of
five cytosine’s at position 62 of the MP segment and
another of four adenine’s at the same position of the PA
segment. When sites on the template were limited to
those that were outside of hps+ regions of length four or
more this peak was removed (Figure 7C, inset). Given
that genome defined hps+ regions explains the majority
of platform-induced variation this uniform trend is not
unusual. If this trend was not present it would suggest
that read location plays a significant role in the intro-
duction of variation, but, after taking the hps+ regions
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into account, there is little variation left to explain. For
the Illumina data there is a non-linear relationship
between read location and observed variability (Figure
7B, D and 7F). Here however it should be noted that for
insertions and deletions the overall rates are two orders
of magnitude less than in their 454 counterparts, again,
reflecting the robustness of the Illumina platform to the
introduction of erroneous indels.
The proportion of nucleotide sites across each patient
that contain differences to the consensus was calculated
(Figure 8A). Although the underlying rates for mis-
matches are similar between both platforms the Illumina
data contains far more sites harboring low-level varia-
tion. This is a result of the characteristically much
higher levels of coverage obtained from this platform.
The proportion of sites across the template that con-
tained variability unique to one of the platforms was
then plotted against a range of threshold values that
defined the extent of variation allowed between plat-
forms before a site was considered to be in disagree-
ment (Figure 8B). Threshold values were based on
percentiles across the distribution of rate differences
(Figure 5). For example, at the threshold value of 30 any
values between 0 plus or minus the 30th percentile value
of rate differences was considered to be in agreement,
and any value outside of this range was not in agree-
ment. Intuitively as the threshold is increased the pro-
portion of sites in agreement between both platforms is
observed to increase. For the 454 data at low threshold
levels, the proportion of sites harboring mismatches not
confirmed on the Illumina platform, at 0.15, is low.
However, on the Illumina platform, at the same low
threshold levels, the proportion of sites harboring low-
level variation, not confirmed on the 454 platform, is
0.85. It is only at threshold levels above the 60th percen-
tile that both platforms start to agree with each other
consistently.
Both frequency and base quality are usually used as an
indication of the reliability of the observed variation. To
visualize the relationship between (i) the percent of non-
consensus nucleotides at a site, (ii) the quality of nucleo-
tide calls, and (iii) the number of sites verified within each
individual sample on both platforms, percentiles were
used to select incrementing minimum threshold values for
quality and variation. For each parameter set, the number
of sites across all patients with variation and quality
greater than or equal to the values used for both platforms
could be identified (Figure 9). For example, if the ith site
within the data from an individual patient obtained from
the 454 platform had both variation and quality above the
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selected percentile value for that platform, but the corre-
sponding site within the Illumina data fell below one or
both of the Illumina percentile values, the site would not
be counted. Alternatively if the ith site on the Illumina
platform also had variation and quality greater than or
equal to the Illumina selected percentile values then the
site would be counted. Thus, this provides a method of
identifying variable sites containing a minimum level of
variation, associated with a minimum quality, that has
been cross-validated on both platforms. Three examples of
such site identification are depicted (Figure 9, inset). An
interesting feature of this topology is between the 55th and
56th quality score percentile, there is a marked decrease in
the number of sites identified across all non-consensus
values. On the 454 platform the quality values at these
percentiles was 36 and 37, respectively, while on the Illu-
mina platform the corresponding quality values were 13
and 14. If variable sites are not validated using the Illu-
mina platform the number of sites identified within each
of the 12 samples is consistently higher (Figure 10). Across
all 6000 parameter pairs queried the median number of
variable sites identified is 1947, just under three times
higher than when cross-platform validation was performed
(median: 662) (Figure 10, inset). If data from the Illumina
platform was used without validation from the 454 plat-
form, the number of variable sites obtained is consistently
higher than both previous searches since the number of
sites containing low-level variation exceeds that within the
454 data.
Discussion
Here we have developed a framework for the compari-
son of next generation data derived from multiple
sources. We have applied the framework to the compar-
ison of platform dependent error rates present within
data generated on both the 454 Life Sciences and Illu-
mina platforms. Other applications include the compari-
son of temporally sampled data or data derived from
different tissues within the host. Given that novel next
generation sequencing platforms and chemistries are
being developed, ease of comparison of data from differ-
ent sources is timely. Our software permits the efficient
analysis of multiple such data sets within one integrated
framework. We demonstrate its usage by comparing
extremely large data sets of influenza H1N1 samples
sequenced on both the 454 Life Sciences and Illumina
platforms. Previously we have demonstrated how phylo-
genetic trees can be inferred from combined time points
of viral data, permitting the tracking of the emergence
of distinct viral lineages associated with HIV-1 drug
resistance forms [3,35].
To determine the importance of characterizing the
extent of platform induced variation in this study we
compared the entropy present within the read data
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derived from the 12 H1N1/09 samples to that of a sam-
ple of data from GenBank (Figure 4C). We observed
that the median entropies obtained from reads pooled
according to platform were higher than those obtained
from the GenBank data, thus, highlighting the impor-
tance of quantifying how much of this variation was
caused by platform error, prior to the detection of genu-
ine variants. In order to quantify this we considered any
differences in variation between the data from each of
the platforms as being platform dependent (Figure 5).
Following the calculation of the per site ratios between
variant and consensus frequencies, it was observed that
for insertions and deletions the ratios within the 454
data were significantly higher than their Illumina coun-
terparts (Figure 6A). The higher ratios were strongly
associated with hps+ regions (Figure 6B), a characteristic
that has been previously observed, for example, within a
study designed to characterize platform error using the
reverse transcriptase gene of HIV-1 [7]. This result
highlights the suitability of the Illumina technology for
viral data sets, which is often prone to high levels of
biologically relevant indels.
While mapping of low frequency variation at sites on
the template to locations within the underlying reads it
was observed that within the 454 data, with the excep-
tion of the read starts, the frequencies follow a random
expectation (Figure 7A, C and 7E). This is unsurprising
given the observation that the majority of platform-
induced variation is dependent on the location of sites
in relation to hps+ regions (Figure 6B), as defined by the
genome. Since these regions are located randomly in
relation to the read, platform dependent variation would
be expected to appear randomly with respect to read
length. The major implication of this is that that error
occurring at particular positions on a genome may be
replicated across multiple independent samples, as has
been previously observed [27]. It also suggests, that
within the 454 data the genomic positioning of hps+
sites can be used to accurately predict where this error
is likely to occur, and that steps can be taken to reduce
its effects on data analysis, such as the removal of inser-
tions within reads that fall with hps+ regions and that
are associated with low quality scores. Conversely within
the data obtained from the Illumina platform the distri-
butions of indel error in relation to read location does
not fall consistently within the random expectation (Fig-
ure 7B, D and 7F). For this data hps+ regions were not
observed to influence location. Combined, this suggests
that read location plays an influential role in the intro-
duction of such error, although the levels present, espe-
cially given the far higher coverage, are extremely low.
For mismatches, ratios between consensus and variant
frequencies were observed to be relatively similar on
both platforms, although as a result of higher coverage
many more sites within the Illumina data harbored low-
level change (Figure 8A and 8B). To demonstrate the
applicability of our software to data sets derived from
different sources the topology generated by the number
of variable sites cross-validated using both platforms, in
relation to the quality of the nucleotides present was
plotted (Figure 9). The topology follows the general
trend of high non-consensus and quality score values
lead to few polymorphic sites, low non-consensus and
quality score thresholds lead to many polymorphic sites.
Of particular interest, however, is that between the 55th
and 56th quality percentiles there is a consistent
decrease in the number of variable sites identified, sug-
gesting a possible cutoff value for this parameter. Inter-
estingly, quality alone does not appear to be sufficient
for accurately identifying the presence of low-level bio-
logical variation as, without cross-validation using the
Illumina platform, the number of sites identified within
each sample is consistently higher (Figure 10). In the
latter the median number of variable sites across all 12
samples is 1947, which is almost three times higher
than when cross-platform validation is performed.
Reflecting this uncertainty is the development of many
probabilistic methods that attempt to improve the relia-
bility of identifying low-level variation at sites within
data obtained from a single platform [36-39]. Our fra-
meworks ability to store temporally sampled data pro-
vides an opportunity to derive a set of priors
characterizing the expected variation within that indivi-
dual. Combined with the error rates described here and
in conjunction with read quality scores this forms the
bases for our first future update which involves filtering
platform dependent variation from temporally sampled
read data using a Bayesian approach.
Conclusion
We have provided software, Segminator II, which can be
used for the processing of temporally, spatially or other-
wise linked viral data obtained from next generation
sequencing platforms. In a demonstration of the usabil-
ity of our software we have also quantified the amount
of platform dependent error that is present within data
generated on both the 454 and Illumina platforms and,
thus, highlighted the need for care when calling low fre-
quency variants using a single platform. Given that next
generation data is increasingly important in the analysis
of drug-resistance and vaccine trials, this software will
be useful to the retroviral research community.
Availability and requirements
Project name: Segminator II
Project home page: http://www.bioinf.manchester.ac.
uk/segminator/
Operating system: e.g. Platform independent
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Programming language: Java
Other requirements: Java 1.6 or higher
License: GNU Lesser GPL
Any restrictions to use by non-academics: license
needed
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